Vetter Dedicates New Facility in Suburban Chicago
“For injectable drugs, collaboration early in development is essential,” said Peter Soelkner, Vetter`s managing director. “What is the most user-friendly injection system for the patient? Should the compound be liquid or freeze-dried and reconstituted? What delivery system would best ensure multinational regulatory approval? Getting the answers right — the first time — speeds medications to market and to the patients that need them.”
The Skokie site at 8025 Lamon Avenue, Vetter’s first U.S. facility and its first outside Germany, will eventually employ 50 to 60 highly skilled professionals.
“Since nearly half of our customer base is located in North America, creating a U.S. facility was the logical next step,” said Soelkner. “Although we did consider several other U.S. biotech hotspots, including Boston and San Francisco, Chicago best suited our needs.”
Most read news
Organizations
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.